The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing.
The new Carterra Vega HT-SPR system combines 48 parallel channels with high-resolution binding data, enabling primary screening at a scale previously unattainable with label-free technologies.
A new class of small-molecule drugs could represent a therapeutic modality aimed at eliminating disease-causing proteins before they spread in the body.